39 completed, 4 unknown, 3 withdrawn, 2 terminated. 24 Phase 4, 10 Phase 3, 7 Not applicable, 4 Phase 2, 2 Phase 1.
Follow dorzolamide: new trials by email Literature Review of dorzolamide trials Research Report on dorzolamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety Dorzolamide / Timolol Ophthalmic Solution, dorzolamide/timolol - Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Completed | Laboratorios Poen | 84 | 2023-03-07 | 2024-11-06 |
| Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide, Injections of 1.25 mg of intravitreal bevacizumab with artificial tears - Diabetic Macular Edema | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 62 | 2021-10-06 | 2021-10-19 |
| Augmented Macular Pigment-containing Nutraceutical and Central Visual Function Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo - Glaucoma, Glaucoma Eye | Phase 4 | Withdrawn | University of the Incarnate Word | 2021-05-01 | 2022-10-04 | |
| Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses timolol maleate and dorzolamide hydrochloride - Glaucoma | Phase 1 | Completed | University of Florida | 2 | 2018-01-18 | 2021-12-02 |
| PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic - Primary Open-angle Glaucoma | Phase 3 | Terminated | Laboratorios Sophia S.A de C.V. | 51 | 2017-11-06 | 2025-03-06 |
| Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml Dorzol 20 mg/ml, Trusopt 20 mg/ml - Primary Open Angle Glaucoma of Both Eyes | Phase 3 | Completed | Jadran Galenski laboratorij d.d. | 118 | 2017-04-05 | 2023-08-02 |
| KJ-TFC-004 Drug-drug Interaction Study [A], [B], [A]+[B](1) - Glaucoma, Eye Diseases | Phase 1 | Completed | Kukje Pharma | 32 | 2016-12-01 | 2018-04-11 |
| Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) PRO-122, Krytantek Ofteno® - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Laboratorios Sophia S.A de C.V. | 60 | 2016-04-01 | 2019-12-09 |
| Stop Retinal Ganglion Cell Dysfunction Study Latanoprost, Bimatoprost, Travoprost - Glaucoma | Phase 3 | Terminated | University of Miami | 28 | 2015-09-01 | 2025-08-26 |
| 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy tafluprost, tafluprost and dorzolamide/timolol - Glaucoma, Ocular Surface Disease | Phase 4 | Completed | Aristotle University Of Thessaloniki | 43 | 2015-03-01 | 2020-12-17 |
| Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, Subject's habitual PGA monotherapy - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon, a Novartis Company | 218 | 2014-12-01 | 2016-12-08 |
| Pupillary Response After Glaucoma Medication Latanoprost, Timolol, Dorzolamide - Drug Effect (Glaucoma Drugs) | Not applicable | Completed | Glostrup University Hospital, Copenhagen | 21 | 2014-05-01 | 2015-08-13 |
| Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema Dorzolamide hydrochloride (2%), Placebo Sodium hyaluronate 4mg - Diabetic Retinopathy, Diabetic Macular Edema | Unknown | Hospital Juarez de Mexico | 60 | 2014-01-01 | 2015-03-20 | |
| Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma Brimonidine Tartrate, Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops, Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension - Glaucoma, Open-Angle | Phase 4 | Completed | Afyon Kocatepe University Hospital | 96 | 2014-01-01 | 2019-05-29 |
| Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution - Glaucoma, Ocular Hypertension | Phase 3 | Withdrawn | Allergan | 2013-07-01 | 2013-07-18 | |
| Clinical Evaluation of Patients With X-linked Retinoschisis Dorzolamide 2% TID or brinzolamide 1% TID - X-linked Retinoschisis, XLRS | Completed | Beacon Therapeutics | 66 | 2012-11-01 | 2017-11-17 | |
| Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Aqueous Suppressant Eye Drops - Glaucoma | Phase 4 | Unknown | Credit Valley EyeCare | 150 | 2012-02-01 | 2017-07-21 |
| Patient Preference Comparison of AZARGA Versus COSOPT Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension, Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon Research | 112 | 2011-09-01 | 2014-02-10 |
| The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops - Scleral Buckling | Not applicable | Completed | Jason Hsu, MD | 21 | 2011-06-01 | 2018-05-30 |
| Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma Brinzolamide/Timolol Maleate Fixed Combination (AZARGA), Dorzolamide/timolol Maleate Fixed Combination (COSOPT) - Glaucoma | Phase 4 | Completed | Alcon Research | 120 | 2010-09-01 | 2016-11-21 |
Showing 20 of 48. Sign in to see all of them.
Glaucoma (26) · Ocular Hypertension (22) · Glaucoma, Open-Angle (21) · Diabetic Retinopathy (2) · Eye Diseases (2) · Exfoliation Syndrome (1) · Hydrophthalmos (1) · Retinal Degeneration (1) · Retinal Detachment (1) · Retinal Perforations (1) · Retinoschisis (1)
Alcon Research (6) · Pharmaceutical Research Network (4) · Aristotle University Of Thessaloniki (3) · Allergan (2) · Laboratorios Sophia S.A de C.V. (2) · Afyon Kocatepe University Hospital (1) · Alcon, a Novartis Company (1) · Alfred E. Tiefenbacher (GmbH & Co. KG) (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Beacon Therapeutics (1) · Bp Consulting, Inc (1) · Credit Valley EyeCare (1) · Glostrup University Hospital, Copenhagen (1) · Hospital Juarez de Mexico (1) · Innovative Medical (1)
United States (15) · Canada (7) · Argentina (2) · Denmark (2) · Greece (2) · Italy (2) · Mexico (2) · Austria (1) · Brazil (1) · Colombia (1) · Germany (1) · Iran (1) · Japan (1) · Russia (1) · Slovenia (1)
William C. Stewart, MD (4) · Elizabeth D. Sharpe, MD (2) · Jason Hsu, MD (2) · Sriram Sonty, MD, FACS (2) · Abayomi Ogundele, PharmD (1) · Amandeep S Rai, MD (1) · Anastasios G Konstas, MD, PhD (1) · Anastasios GP Konstas, MD, PhD (1) · Anastasios Konstas, MD, phD (1) · Anthony D Realini, MD (1) · Barbara Cvenkel, MD (1) · Carl B Camras, MD (1) · Chris Hudson, PhD (1) · Cindy M. Hutnik, BSc, PhD, MD (1)
PMID 19476406, PMID 12614754, PMID 14509472, PMID 16303952, PMID 17102003, PMID 18834580, PMID 19365194, PMID 21878847, PMID 21960068, PMID 22332206, PMID 24212847, PMID 27312975, PMID 2788589, PMID 27913991, PMID 28957960, PMID 29680880, PMID 30551202, PMID 35909461, PMID 38376643, PMID 41737851, PMID 8562550, PMID 9261306
2008 (1), R01EY014957 (1)